The company plans to raise money this fall to support the continued development of its head-and-neck cancer testing platform and oral squamous cell carcinoma test.

On September 12, TD Cowen analyst Brendan Smith reaffirmed a Buy rating on Twist Bioscience Corp. (NASDAQ:TWST) with a $36 price target. His note followed the company’s September 9 presentation at the ...

Born from personal experience and backed by scientific excellence, MYmAb Biologics is leading a quiet revolution in cancer research—anchored in Malaysia, aiming for the world.